Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496309 | 0.82 | MAPT (0.53) | KCNH2MAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL4508638 | 0.79 | KMT2A (0.55) | KCNH2MAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL4508645 | 0.79 | KMT2A (0.55) | KCNH2MAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL4508643 | 0.79 | KMT2A (0.55) | KCNH2MAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL14425348 | 0.77 | KDM4E (0.46) | MAPTSMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL4503345 | 0.76 | MAPT (0.53) | MAPTSMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL4503337 | 0.76 | MAPT (0.53) | MAPTSMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL4496216 | 0.75 | KMT2A (0.53) | KCNH2MAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL4495816 | 0.72 | KMT2A (0.58) | KCNH2MAPTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL4495811 | 0.72 | KMT2A (0.58) | KCNH2MAPTSMN1; SMN2NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638540-B2 | Benzofuran compound and medicinal composition containing the same | THE NEW INDUSTRY RESEARCH ORGANIZATION (JP) | 2009-12-29 | — | — | US | disclosed |
| US-7638540-B2 | Benzofuran compound and medicinal composition containing the same | THE NEW INDUSTRY RESEARCH ORGANIZATION (JP) | 2009-12-29 | — | — | US | disclosed |
| US-7638540-B2 | Benzofuran compound and medicinal composition containing the same | THE NEW INDUSTRY RESEARCH ORGANIZATION (JP) | 2009-12-29 | — | — | US | disclosed |
| US-20060194851-A1 | Benzofuran compound and medicinal composition containing the same | NEW INDUSTRY RESEARCH ORGANIZATION, THE (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1627873-A1 | BENZOFURAN COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | The New Industry Research Organization (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194851-A1 | Benzofuran compound and medicinal composition containing the same | LTB4R2, LTC4S, LTB4R | KCNH2 849/4885MAPT 1497/4885SMN1; SMN2 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.